

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Imoxat 40 mg / 4 mg spot-on solution for small cats and ferrets

Imoxat 80 mg / 8 mg spot-on solution for large cats

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

### Active substances:

Each unit dose (pipette) delivers:

|                                                  | Unit dose | Imidacloprid | Moxidectin |
|--------------------------------------------------|-----------|--------------|------------|
| Imoxat for small cats ( $\leq 4$ kg) and ferrets | 0.4 ml    | 40 mg        | 4 mg       |
| Imoxat for large cats ( $> 4-8$ kg)              | 0.8 ml    | 80 mg        | 8 mg       |

### Excipients:

| Qualitative composition of excipients and other constituents | Quantitative composition if that information is essential for proper administration of the veterinary medicinal product |
|--------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| Benzyl alcohol                                               |                                                                                                                         |
| Butylhydroxytoluene (E321)                                   | 1 mg/ml                                                                                                                 |
| Propylene carbonate                                          |                                                                                                                         |

Colourless to yellow solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Cats, ferrets.

### 3.2 Indications for use for each target species

**For cats** suffering from, or at risk from, mixed parasitic infections. The veterinary medicinal product is only indicated when use against fleas and one or more of the other target parasites is indicated at the same time:

- the treatment and prevention of flea infestation (*Ctenocephalides felis*),
- the treatment of ear mite infestation (*Otodectes cynotis*),
- the treatment of notoedric mange (*Notoedres cati*),
- the treatment of the lungworm *Eucoleus aerophilus* (syn. *Capillaria aerophila*) (adults),
- the prevention of lungworm disease (L3/L4 larvae of *Aelurostrongylus abstrusus*),
- the treatment of the lungworm *Aelurostrongylus abstrusus* (adults),
- the treatment of the eye worm *Thelazia callipaeda* (adults),
- the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*),
- the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara cati* and *Ancylostoma tubaeforme*).

The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

**For ferrets** suffering from, or at risk from, mixed parasitic infections. The veterinary medicinal product is only indicated when use against fleas and the prevention of heartworm disease is indicated at the same time:

- the treatment and prevention of flea infestation (*Ctenocephalides felis*),
- the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*).

### **3.3 Contraindications**

Do not use in kittens under 9 weeks of age.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

For ferrets: do not use Imoxat for large cats (0.8 ml) or Imoxat for dogs (any size).

Do not use in dogs. Instead, the corresponding “Imoxat for dog” product, which contains 100 mg/ml imidacloprid and 25 mg/ml moxidectin, must be used for dogs.

Do not use on canaries.

### **3.4 Special warnings**

The veterinary medicinal product’s efficacy has not been tested in ferrets weighing over 2 kg and therefore the duration of effect might be shorter in these animals.

Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the veterinary medicinal product.

The possibility that other animals in the same household can be a source of re-infection with fleas, mites, gastrointestinal nematodes, heartworm and/or lungworm should be considered, and these should be treated as necessary with an appropriate product.

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each individual animal.

### **3.5 Special precautions for use**

Special precautions for safe use in the target species:

The treatment of cats weighing less than 1 kg and ferrets weighing less than 0.8 kg should be based on a benefit-risk assessment.

There is limited experience on the use of the veterinary medicinal product in sick and debilitated animals, thus the veterinary medicinal product should only be used based on a benefit-risk assessment for these animals.

Do not apply in the mouth, in the eyes or the ears of the animal.

Care should be taken that the veterinary medicinal product is not ingested by animals and does not come into contact with the eyes or mouth of the recipient and/or other animals.

Consider carefully the correct application method described in section 3.9, especially that the veterinary medicinal product should be applied to the site specified in order to minimise the risk for the animal to lick the veterinary medicinal product.

Do not allow recently treated animals to groom each other. Do not allow treated animals to come into contact with untreated animals until the application site is dry.

In case of accidental oral uptake, symptomatic treatment should be administered. There is no known specific antidote. The use of activated charcoal may be beneficial.

It is recommended that cats and ferrets living in, or travelling to areas endemic for heartworm are treated monthly with the veterinary medicinal product to protect them from heartworm disease.

Whilst the accuracy of diagnosis of heartworm infection is limited, it is recommended that attempts be made to check the heartworm status of any cat and ferret aged over 6 months, before beginning prophylactic treatment, as use of the veterinary medicinal product on cats or ferrets which have adult heartworms may cause serious adverse effects, including death. If adult heartworm infection is diagnosed, the infection should be treated in accordance with current scientific knowledge.

In certain individual cats *Notoedres cati* infestation may be severe. In these severe cases concomitant supportive treatment is necessary as treatment with the veterinary medicinal product alone may not be sufficient to prevent death of the animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Avoid contact with skin, eyes or mouth.

Do not eat, drink or smoke during application.

Wash hands thoroughly after use.

After application do not stroke or groom animals until the application site is dry.

In case of accidental spillage onto skin, wash off immediately with soap and water.

People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the veterinary medicinal product with caution. In very rare cases the veterinary medicinal product may cause skin sensitisation or transient skin reactions (for example numbness, irritation or burning/tingling sensation).

In very rare cases the veterinary medicinal product may cause respiratory irritation in sensitive individuals.

If the veterinary medicinal product accidentally gets into eyes, they should be thoroughly flushed with water.

If skin or eye symptoms persist, or the veterinary medicinal product is accidentally swallowed, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

None.

Other precautions:

The solvent in the veterinary medicinal product may stain or damage certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

Imidacloprid is toxic for birds, especially canaries.

### 3.6 Adverse events

Cats and ferrets

|                                                     |                                                                                                                                       |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Rare<br>(1 to 10 animals / 10 000 animals treated): | Application site greasy fur <sup>1</sup><br>Vomiting <sup>1</sup><br>Hypersensitivity reactions <sup>6</sup><br>Erythema <sup>1</sup> |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                      |                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Very rare<br>( $<1$ animal / 10 000 animals treated,<br>including isolated reports): | Behavioural disorder (e.g. agitation) <sup>2</sup><br>Hypersalivation <sup>4</sup><br>Neurological signs <sup>3</sup><br>Pruritus <sup>5</sup><br>Lethargy <sup>2</sup> , Inappetence <sup>2</sup> |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<sup>1</sup>These signs disappear without further treatment.

<sup>2</sup>Transiently noted and related to sensation at application site.

<sup>3</sup>If the animal licks the application site after treatment, (most of which are transient).

<sup>4</sup>The veterinary medicinal product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application site.

<sup>5</sup>Transient in cats.

<sup>6</sup>Local.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

#### Pregnancy, lactation and fertility:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species. Therefore, the use of the product is not recommended in animals intended for breeding or during pregnancy and lactation.

### 3.8 Interaction with other medicinal products and other forms of interaction

During treatment with the veterinary medicinal product no other antiparasitic macrocyclic lactone should be administered.

No interactions between the veterinary medicinal product and routinely used veterinary medicinal products or medical or surgical procedures have been observed.

### 3.9 Administration routes and dosage

To ensure a correct dosage, body weight should be determined as accurately as possible.

#### Dosage schedule for cats

The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 1 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight of the veterinary medicinal product.

For treatment or prevention of infestations with the parasites indicated for use of this veterinary medicinal product, the need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal's lifestyle.

| Weight of cat [kg] | Pipette size to be used                 | Volume [ml] | Imidacloprid [mg/kg bodyweight] | Moxidectin [mg/kg bodyweight] |
|--------------------|-----------------------------------------|-------------|---------------------------------|-------------------------------|
| $\leq 4$ kg        | Imoxat for small cats and ferrets       | 0.4         | minimum of 10                   | minimum of 1                  |
| $> 4$ –8 kg        | Imoxat for large cats                   | 0.8         | 10–20                           | 1–2                           |
| $> 8$ kg           | the appropriate combination of pipettes |             |                                 |                               |

Flea treatment and prevention (*Ctenocephalides felis*)

One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine animal treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The veterinary medicinal product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

Treatment of ear mite infestation (*Otodectes cynotis*)

A single dose of the veterinary medicinal product should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

Treatment of notoedric mange (*Notoedres cati*)

A single dose of the veterinary medicinal product should be administered.

Treatment of the lungworm *Eucoleus aerophilus* (syn. *Capillaria aerophila*) (adults)

A single dose of the veterinary medicinal product should be administered.

Prevention of *Aelurostrongylus abstrusus*

The veterinary medicinal product should be administered monthly.

Treatment of *Aelurostrongylus abstrusus*

The veterinary medicinal product should be administered monthly for three consecutive months.

Treatment of the eye worm *Thelazia callipaeda* (adults)

A single dose of the veterinary medicinal product should be administered.

Heartworm prevention (*Dirofilaria immitis*)

Cats in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with the veterinary medicinal product, the advice provided in section 3.5 should be considered.

For prevention of heartworm disease, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The veterinary medicinal product may be administered throughout the year. The first dose may be given after first possible exposure to mosquitoes, but not more than one month after this exposure. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with the veterinary medicinal product must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of cats having heartworm. Therefore, they can be treated without special precautions.

Roundworm and hookworm treatment (*Toxocara cati* and *Ancylostoma tubaeforme*)

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Dosage schedule for ferrets:

One pipette of Imoxat spot-on solution for small cats (0.4 ml) should be administered per animal.

Do not exceed the recommended dose.

For treatment or prevention of infestations with the parasites indicated for use of this veterinary medicinal product, the need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal's lifestyle.

#### Flea treatment and prevention (*Ctenocephalides felis*)

One treatment prevents future flea infestation for 3 weeks. Under heavy flea pressure it may be necessary to repeat administration after 2 weeks.

#### Heartworm prevention (*Dirofilaria immitis*)

Ferrets in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with the veterinary medicinal product, the advice provided in section 3.5 should be considered.

For prevention of heartworm disease, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The veterinary medicinal product may be administered throughout the year. The first dose may be given after first possible exposure to mosquitoes, but not more than one month after this exposure. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.

In non-endemic areas there should be no risk of ferrets having heartworm. Therefore they can be treated without special precautions.


#### Method of administration


Spot-on use.

For external use only.

Remove one pipette from the package. Tap the narrow part of the pipette to ensure the contents are within the main body of the pipette. Snap back the tip of the pipette to enable the contents to be expelled.

Part the fur on the animal's neck at the base of the skull until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin. Application at the base of the skull will minimise the opportunity for the animal to lick the product. Apply only to undamaged skin.





### 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Up to 10 times the recommended dose was tolerated in cats with no evidence of adverse effects or undesirable clinical signs.

The veterinary medicinal product was administered to kittens at up to 5 times the recommended dose, every 2 weeks for 6 treatments, and there were no serious safety concerns. Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.

After accidental oral ingestion or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur in very rare cases.

The veterinary medicinal product was administered to ferrets at 5 times the recommended dose, every 2 weeks for 4 treatments, and there was no evidence of adverse effects or undesirable clinical signs.

### 3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

### 3.12 Withdrawal periods

Not applicable.

## 4. PHARMACOLOGICAL INFORMATION

### 4.1 ATCvet code: QP54AB52.

### 4.2 Pharmacodynamics

Imidacloprid, 1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamine is an ectoparasiticide belonging to the chloronicotinyl group of compounds. Chemically, it is more accurately described as a chloronicotinyl nitroguanidine. Imidacloprid is active against larval flea stages and adult fleas. Flea larvae in the pet's surroundings are killed after contact with a pet treated with the product. Imidacloprid has a high affinity for the nicotinic acetylcholine receptors in the post-synaptic region of the central nervous system (CNS) of the flea. The ensuing inhibition of cholinergic transmission in insects results in paralysis and death. Due to the weak nature of the interaction with mammalian nicotinic receptors and the postulated poor penetration through the blood-brain barrier in mammals, it has virtually no effect on the mammalian CNS. Imidacloprid has minimal pharmacological activity in mammals.

Moxidectin, 23-(O-methyloxime)-F28249 alpha is a second-generation macrocyclic lactone of the milbemycin family. It is a parasiticide which is active against many internal and external parasites. Moxidectin is active against larval stages (L3, L4) of *Dirofilaria immitis*. It is also active against



gastrointestinal nematodes. Moxidectin interacts with GABA and glutamate-gated chloride channels. This leads to opening of the chloride channels on the postsynaptic junction, the inflow of chloride ions and induction of an irreversible resting state. The result is flaccid paralysis of affected parasites, followed by their death and/or expulsion. The veterinary medicinal product has a persistent action and protects cats for 4 weeks after a single application against reinfection with *Dirofilaria immitis*.

### **4.3 Pharmacokinetics**

After topical administration of the veterinary medicinal product, imidacloprid is rapidly distributed over the animal's skin within one day of application. It can be found on the body surface throughout the treatment interval. Moxidectin is absorbed through the skin, reaching maximum plasma concentrations approximately 1 to 2 days after treatment in cats. Following absorption from the skin, moxidectin is distributed systemically throughout the body tissues but due to its lipophilicity it is concentrated mainly in the fat. It is slowly eliminated from the plasma as manifested by detectable moxidectin concentrations in plasma throughout the treatment interval of one month.

The mean  $T_{1/2}$  in cats ranges between 18.7 and 25.7 days. Studies evaluating the pharmacokinetic behaviour of moxidectin after multiple applications have indicated that steady state serum levels are achieved following approximately 4 consecutive monthly treatments in cats.

### **Environmental properties**

Moxidectin has been classified as persistent, bioaccumulative and toxic in the environment. See section 5.5.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Not applicable.

### **5.2 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.

### **5.3 Special precautions for storage**

Store in the original package in order to protect from light and moisture.  
Do not store above 25 °C.

### **5.4 Nature and composition of immediate packaging**

Pipette: a white pipette composed of a heat-formed shell composed of (polypropylene (PP)/cyclic olefin copolymer (COC)/ethylene vinyl alcohol (EVOH)/polypropylene (PP) with a snap off cap.

Sachet: polyethylene (PET)/aluminium foil/nylon/low density polyethylene (LDPE).

#### Pack sizes

Imoxat for small cats and ferrets: 0.4 ml per pipette.

Imoxat for large cats: 0.8 ml per pipette.

Each cardboard box contains 1 or 3 pipettes in individual foil sachets.

Not all pack sizes may be marketed.

## **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as this may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Limited.

## **7. MARKETING AUTHORISATION NUMBER(S)**

Imoxat for small cats and ferrets :

EU/2/21/280/001 (3 pipettes)

EU/2/21/280/007 (1 pipette)

Imoxat for large cats :

EU/2/21/280/002 (3 pipettes)

EU/2/21/280/008 (1 pipette)

## **8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 07/12/2021

## **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{MM/YYYY}

## **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Imoxat 40 mg / 10 mg spot-on solution for small dogs  
Imoxat 100 mg / 25 mg spot-on solution for medium dogs  
Imoxat 250 mg / 62.5 mg spot-on solution for large dogs  
Imoxat 400 mg / 100 mg spot-on solution for extra-large dogs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

### Active substances:

Each unit dose (pipette) delivers:

|                                              | Unit dose | Imidacloprid | Moxidectin |
|----------------------------------------------|-----------|--------------|------------|
| Imoxat for small dogs ( $\leq 4$ kg)         | 0.4 ml    | 40 mg        | 10 mg      |
| Imoxat for medium dogs ( $> 4$ –10 kg)       | 1.0 ml    | 100 mg       | 25 mg      |
| Imoxat for large dogs ( $> 10$ –25 kg)       | 2.5 ml    | 250 mg       | 62.5 mg    |
| Imoxat for extra-large dogs ( $> 25$ –40 kg) | 4.0 ml    | 400 mg       | 100 mg     |

### Excipients:

| Qualitative composition of excipients and other constituents | Quantitative composition if that information is essential for proper administration of the veterinary medicinal product |
|--------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| Benzyl alcohol                                               |                                                                                                                         |
| Butylhydroxytoluene (E321).                                  | 1 mg/ml                                                                                                                 |
| Propylene carbonate                                          |                                                                                                                         |

Colourless to yellow solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Dogs.

### 3.2 Indications for use for each target species

**For dogs** suffering from, or at risk from, mixed parasitic infections. The veterinary medicinal product is only indicated when use against fleas and one or more of the other target parasites is indicated at the same time:

- the treatment and prevention of flea infestation (*Ctenocephalides felis*),
- the treatment of biting lice (*Trichodectes canis*),
- the treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*),
- the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*),
- the treatment of circulating microfilariae (*Dirofilaria immitis*),
- the treatment of cutaneous dirofilariosis (adult stages of *Dirofilaria repens*)
- the prevention of cutaneous dirofilariosis (L3 larvae of *Dirofilaria repens*),
- the reduction of circulating microfilariae (*Dirofilaria repens*),
- the prevention of angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus*)

- *vasorum*),
- the treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis*,
- the prevention of spirocercosis (*Spirocerca lupi*),
- the treatment of *Eucoleus* (syn. *Capillaria*) *boehmi* (adults),
- the treatment of the eye worm *Thelazia callipaeda* (adults),
- the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).

The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

### 3.3 Contraindications

Do not use in puppies under 7 weeks of age.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

Do not use in dogs classified as Class 4 for heartworm disease as the safety of the product has not been evaluated in this animal group.

Do not use in cats. Instead, the corresponding “Imoxat for cats” product (0.4 or 0.8 ml), which contains 100 mg/ml imidacloprid and 10 mg/ml moxidectin, must be used for cats.

Do not use in ferrets. Only “Imoxat for small cats and ferrets” (0.4 ml) must be used for ferrets. .

Do not use on canaries.

### 3.4 Special warnings

Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the veterinary medicinal product.

The possibility that other animals in the same household can be a source of re-infection with fleas, mites, gastrointestinal nematodes, heartworm and/or lungworm should be considered, and these should be treated as necessary with an appropriate product.

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each individual animal.

Efficacy against adult *Dirofilaria repens* has not been tested under field conditions.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

The treatment of animals weighing less than 1 kg should be based on a benefit-risk assessment.

There is limited experience on the use of the veterinary medicinal product in sick and debilitated animals, thus the veterinary medicinal product should only be used based on a risk-benefit assessment for these animals.

Do not apply in the mouth, in the eyes or the ears of the animal.

Care should be taken that the veterinary medicinal product is not ingested by animals and does not come into contact with the eyes or mouth of the recipient and/or other animals. Consider carefully the correct application method described in section 3.9, especially that the veterinary medicinal product should be applied to the site specified in order to minimise the risk for the animal to lick the veterinary medicinal product.

Do not allow recently treated animals to groom each other. Do not allow treated animals to come into contact with untreated animals until the application site is dry.

In case of accidental oral uptake, symptomatic treatment should be administered. There is no known specific antidote. The use of activated charcoal may be beneficial.

When the veterinary medicinal product is applied in 3 to 4 separate spots (see section 3.9), specific care should be taken to prevent the animal licking the application sites.

This veterinary medicinal product contains moxidectin (a macrocyclic lactone), therefore special care should be taken with Collies, Old English Sheepdogs and related breeds or crossbreeds, to correctly administer the veterinary medicinal product as described under section 3.9; in particular, oral uptake by Collie or Old English Sheep dogs and related breeds or crossbreeds should be prevented.

The safety of the veterinary medicinal product has only been evaluated in dogs classified as either Class 1 or 2 for heartworm disease in laboratory studies and in a few Class 3 dogs in a field study. Therefore the use in dogs with obvious or severe symptoms of the disease should be based on a careful benefit risk assessment by the treating veterinarian.

Although experimental overdose studies have shown that the veterinary medicinal product may be safely administered to dogs infected with adult heartworms, it has no therapeutic effect against adult *Dirofilaria immitis*. It is therefore recommended that all dogs 6 months of age or more, living in areas endemic for heartworm, should be tested for existing adult heartworm infection before being treated with the veterinary medicinal product. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of the veterinary medicinal product has not been evaluated when administered on the same day as an adulticide.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Avoid contact with skin, eyes or mouth.  
Do not eat, drink or smoke during application.  
Wash hands thoroughly after use.

After application do not stroke or groom animals until the application site is dry.  
In case of accidental spillage onto skin, wash off immediately with soap and water.  
People with a known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the veterinary medicinal product with caution. In very rare cases the veterinary medicinal product may cause skin sensitisation or transient skin reactions (for example numbness, irritation or burning/tingling sensation).  
In very rare cases the veterinary medicinal product may cause respiratory irritation in sensitive individuals.  
If the veterinary medicinal product accidentally gets into eyes, they should be thoroughly flushed with water.  
If skin or eye symptoms persist, or the veterinary medicinal product is accidentally swallowed, seek medical advice immediately and show the package leaflet or label to the physician.

Special precautions for the protection of the environment:

The veterinary medicinal product should not enter water courses as this may be dangerous for fish and other aquatic organism: moxidectin is highly toxic to aquatic organisms. Dogs should not be allowed to swim in surface waters for 4 days after treatment..

#### Other precautions:

The solvent in Imoxat may stain or damage certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

Imidacloprid is toxic for birds, especially canaries.

### **3.6 Adverse events**

Dogs

|                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Common<br>(1 to 10 animals / 100 animals treated):                             | Cough <sup>1</sup> , Dyspnoea <sup>1</sup> , Tachypnoea <sup>1</sup><br>Diarrhoea <sup>1</sup> , Vomiting <sup>1</sup><br>Inappetence <sup>1</sup> , Lethargy <sup>1</sup>                                                                                                                                                                                                                                |
| Rare<br>(1 to 10 animals / 10 000 animals treated):                            | Vomiting                                                                                                                                                                                                                                                                                                                                                                                                  |
| Very rare<br>(<1 animal / 10 000 animals treated, including isolated reports): | Application site greasy fur <sup>2</sup> , Application site hair loss <sup>2</sup> ,<br>Application site itching <sup>2</sup> , Application site reddening. <sup>2</sup><br>Behavioural changes (eg. agitation) <sup>3</sup><br>Hypersalivation <sup>4</sup><br>Neurological signs (e.g. ataxia, muscle tremor) <sup>5</sup><br>Pruritus <sup>6</sup><br>Inappetence <sup>3</sup> , Lethargy <sup>3</sup> |

<sup>1</sup>In heartworm positive dogs with microfilaraemia there is a risk of gastrointestinal and severe respiratory signs that may require prompt veterinary treatment.

<sup>2</sup>Transient local skin sensitivity reactions, These signs disappear without further treatment.

<sup>3</sup>Transiently noted and related to sensation at application site.

<sup>4</sup>May occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application sites.

<sup>5</sup>Most neurological signs occur transiently.

<sup>6</sup>In dogs, transient.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy, lactation and fertility:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species. Therefore, the use of the product is not recommended in animals intended for breeding or during pregnancy and lactation.

### **3.8 Interaction with other medicinal products and other forms of interaction**

During treatment with the veterinary medicinal product no other antiparasitic macrocyclic lactone should be administered.

No interactions between the veterinary medicinal product and routinely used veterinary medicinal products or medical or surgical procedures have been observed.

Safety of the veterinary medicinal product when administered on the same day as an adulticide to remove adult heartworms has not been evaluated.

### 3.9 Administration routes and dosage

To ensure a correct dosage, body weight should be determined as accurately as possible.

#### Dosage schedule:

The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight of the veterinary medicinal product.

For treatment or prevention of infestations with the parasites indicated for use of this veterinary medicinal product, the need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal's lifestyle.

| Weight of dog [kg] | Pipette size to be used                 | Volume [ml] | Imidacloprid [mg/kg bw] | Moxidectin [mg/kg bw] |
|--------------------|-----------------------------------------|-------------|-------------------------|-----------------------|
| ≤ 4 kg             | Imoxat for small dogs                   | 0.4         | minimum of 10           | minimum of 2.5        |
| > 4–10 kg          | Imoxat for medium dogs                  | 1.0         | 10–25                   | 2.5–6.25              |
| > 10–25 kg         | Imoxat for large dogs                   | 2.5         | 10–25                   | 2.5–6.25              |
| > 25–40 kg         | Imoxat for extra-large dogs             | 4.0         | 10–16                   | 2.5–4                 |
| > 40 kg            | the appropriate combination of pipettes |             |                         |                       |

#### Flea treatment and prevention (*Ctenocephalides felis*)

One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine animal treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The veterinary medicinal product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

#### Treatment of biting lice (*Trichodectes canis*)

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

#### Treatment of ear mite infestation (*Otodectes cynotis*)

A single dose of the veterinary medicinal product should be administered. Loose debris should be gently removed from the external ear canal at each treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

#### Treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*)

A single dose should be administered twice 4 weeks apart.

#### Treatment of demodicosis (caused by *Demodex canis*)

The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against *Demodex canis* and leads to a marked improvement of clinical signs particularly in mild to moderate cases. Especially severe cases may require more prolonged and more frequent treatment. To achieve the best

possible response in these severe cases, at the discretion of the veterinarian, the veterinary medicinal product can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian.

As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

#### Prevention of heartworm disease (*D. immitis*)

Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with the veterinary medicinal product, the advice provided in section 3.5 should be considered.

For prevention of heartworm disease, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit *D. immitis*) are present. The veterinary medicinal product may be administered throughout the year. The first dose may be given after first possible exposure to mosquitoes, but not more than one month after this exposure. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with the veterinary medicinal product must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of dogs having heartworm. Therefore they can be treated without special precautions.

#### Prevention of cutaneous dirofilariosis (skinworm) (*D. repens*)

For prevention of cutaneous dirofilariosis, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit *D. repens* larvae) are present. The veterinary medicinal product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month.

#### Treatment of microfilariae (*D. immitis*)

The veterinary medicinal product should be administered monthly for two consecutive months.

#### Treatment of cutaneous dirofilariosis (skin worm) (adult stages of *Dirofilaria repens*)

The veterinary medicinal product should be administered monthly for six consecutive months.

#### Reduction of microfilariae (skin worm) (*D. repens*)

The veterinary medicinal product should be administered monthly for four consecutive months.

#### Treatment and prevention of *Angiostrongylus vasorum*

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

In endemic areas regular monthly application will prevent angiostrongylosis and patent infection with *Angiostrongylus vasorum*.

#### Treatment of *Crenosoma vulpis*

A single dose should be administered.

#### Prevention of spirocercosis (*Spirocerca lupi*)

The veterinary medicinal product should be administered monthly.



Treatment of *Eucoleus* (syn. *Capillaria*) *boehmi* (adults)

The veterinary medicinal product should be administered monthly for two consecutive months. It is advisable to prevent auto-coprohagia between the two treatments in order to prevent possible reinfection.

Treatment of the eye worm *Thelazia callipaeda* (adults)

A single dose of the veterinary medicinal product should be administered.

Roundworm, hookworm and whipworm treatment (*Toxocara canis*, *Ancylostoma caninum*, *Uncinaria stenocephala*, *Toxascaris leonina* and *Trichuris vulpis*)

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Studies have shown that monthly treatment of dogs will prevent infections caused by *Uncinaria stenocephala*.

Method of administration

Spot-on use.

For external use only.


Remove one pipette from the package. Tap the narrow part of the pipette to ensure the contents are within the main body of the pipette. Snap back the tip of the pipette to enable the contents to be expelled.


For dogs up to 25 kg:

With the dog in a standing position, part the coat between the shoulder blades until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin.

For dogs of more than 25 kg:

For easy application the dog should be standing. The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail. At each spot, part the coat until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin. Do not apply an excessive amount of solution at any one spot, as that could cause some of the product to run down the animal's side.





### 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Up to 10 times the recommended dose was tolerated in adult dogs with no evidence of adverse effects or undesirable clinical signs. Five times the recommended minimum dose applied at weekly intervals for 17 weeks was investigated in dogs aged over 6 months and tolerated with no evidence of adverse effects or undesirable clinical signs.

The veterinary medicinal product was administered to puppies at up to 5 times the recommended dose, every 2 weeks for 6 treatments, and there were no serious safety concerns. Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.

After accidental oral ingestion or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur in very rare cases.

Ivermectin-sensitive Collie dogs tolerated up to 5 times the recommended dose repeated at monthly intervals without any adverse effects, but the safety of application at weekly intervals has not been investigated in ivermectin-sensitive Collie dogs. When 40 % of the unit dose was given orally, severe neurological signs were observed. Oral administration of 10 % of the recommended dose produced no adverse effects.

Dogs infected with adult heartworms tolerated up to 5 times the recommended dose, every 2 weeks for 3 treatments, without any adverse effects.

### 3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

### 3.12 Withdrawal periods

Not applicable.

## 4. PHARMACOLOGICAL INFORMATION

### 4.1 ATCvet code: QP54AB52.

### 4.2 Pharmacodynamics

Imidacloprid, 1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamine is an ectoparasiticide belonging to the chloronicotinyl group of compounds. Chemically, it is more accurately described as a chloronicotinyl nitroguanidine. Imidacloprid is active against larval flea stages and adult fleas. Flea larvae in the pet's surroundings are killed after contact with a pet treated with the product. Imidacloprid has a high affinity for the nicotinic acetylcholine receptors in the post-synaptic region of the central nervous system (CNS) of the flea. The ensuing inhibition of cholinergic transmission in insects results in paralysis and death. Due to the weak nature of the interaction with mammalian nicotinic

receptors and the postulated poor penetration through the blood-brain barrier in mammals, it has virtually no effect on the mammalian CNS. Imidacloprid has minimal pharmacological activity in mammals.

Moxidectin, 23-(O-methyloxime)-F28249 alpha is a second-generation macrocyclic lactone of the milbemycin family. It is a parasiticide which is active against many internal and external parasites. Moxidectin is active against larval stages (L3, L4) of *Dirofilaria immitis*. It is also active against gastrointestinal nematodes. Moxidectin interacts with GABA and glutamate-gated chloride channels. This leads to opening of the chloride channels on the postsynaptic junction, the inflow of chloride ions and induction of an irreversible resting state. The result is flaccid paralysis of affected parasites, followed by their death and/or expulsion.

The veterinary medicinal product has a persistent action and protects dogs for 4 weeks after a single application against reinfection with the following parasites: *Dirofilaria immitis*, *Dirofilaria repens*, *Angiostrongylus vasorum*.

### **4.3 Pharmacokinetics**

After topical administration of the veterinary medicinal product, imidacloprid is rapidly distributed over the animal's skin within one day of application. It can be found on the body surface throughout the treatment interval. Moxidectin is absorbed through the skin, reaching maximum plasma concentrations approximately 4 to 9 days after treatment in dogs. Following absorption from the skin, moxidectin is distributed systemically throughout the body tissues but due to its lipophilicity it is concentrated mainly in the fat. It is slowly eliminated from the plasma as manifested by detectable moxidectin concentrations in plasma throughout the treatment interval of one month. The T<sub>1/2</sub> in dogs is about 28.4 days.

Studies evaluating the pharmacokinetic behaviour of moxidectin after multiple applications have indicated that steady state serum levels are achieved following approximately 4 consecutive monthly treatments in dogs.

### **Environmental properties**

Moxidectin has been classified as persistent, bioaccumulative and toxic in the environment.

See sections 3.5. and 5.5.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Not applicable.

### **5.2 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.

### **5.3 Special precautions for storage**

Store in the original package in order to protect from light and moisture.

Do not store above 25 °C.

### **5.4 Nature and composition of immediate packaging**

Pipette: a white pipette composed of a heat-formed shell composed of (polypropylene (PP)/cyclic olefin copolymer (COC)/ethylene vinyl alcohol EVOH)/polypropylene(PP) with a snap-off cap.

Sachet: polyethylene (PET)/aluminium foil/nylon/low density polyethylene (LDPE).

Pack sizes:

Imoxat for small dogs: 0.4 ml per pipette.

Imoxat for medium dogs: 1.0 ml per pipette.

Imoxat for large dogs: 2.5 ml per pipette.

Imoxat for extra-large dogs: 4.0 ml per pipette.

Each cardboard box contains 1 or 3 pipettes in individual foil sachets.

Not all pack sizes may be marketed.

**5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as this may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Limited.

**7. MARKETING AUTHORISATION NUMBER(S)**

Imoxat for small dogs:

EU/2/21/280/003 (3 pipettes)

EU/2/21/280/009 (1 pipette)

Imoxat for medium dogs:

EU/2/21/280/004 (3 pipettes)

EU/2/21/280/010 (1 pipette)

Imoxat for large dogs:

EU/2/21/280/005 (3 pipettes)

EU/2/21/280/011 (1 pipette)

Imoxat for extra-large dogs:

EU/2/21/280/006 (3 pipettes)

EU/2/21/280/012 (1 pipette)

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 07/12/2021

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{MM/YYYY}

## **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**



**PARTICULARS TO APPEAR ON THE OUTER PACKAGE****CARDBOARD BOX****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat 40 mg / 4 mg spot-on solution

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 0.4 ml pipette contains 40 mg imidacloprid and 4 mg moxidectin

**3. PACKAGE SIZE**

1 pipette  
3 pipettes

**4. TARGET SPECIES**

For small cats weighing 4 kg or less and ferrets.

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Spot-on use.  
For external use only.

**7. WITHDRAWAL PERIODS****8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Store in the original package in order to protect from light and moisture.  
Do not store above 25 °C.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

|                                                  |
|--------------------------------------------------|
| <b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b> |
|--------------------------------------------------|

For animal treatment only.

|                                                                    |
|--------------------------------------------------------------------|
| <b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b> |
|--------------------------------------------------------------------|

Keep out of the sight and reach of children.

|                                                       |
|-------------------------------------------------------|
| <b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b> |
|-------------------------------------------------------|

Chanelle Pharmaceuticals Manufacturing Limited.

|                                            |
|--------------------------------------------|
| <b>14. MARKETING AUTHORISATION NUMBERS</b> |
|--------------------------------------------|

EU/2/21/280/001 (3 pipettes)

EU/2/21/280/007 (1 pipette)

|                         |
|-------------------------|
| <b>15. BATCH NUMBER</b> |
|-------------------------|

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARDBOARD BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat 80 mg / 8 mg spot-on solution

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 0.8 ml pipette contains 80 mg imidacloprid and 8 mg moxidectin.

**3. PACKAGE SIZE**

1 pipette  
3 pipettes

**4. TARGET SPECIES**

For large cats weighing >4 to 8 kg.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Spot-on use.  
For external use only.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Store in the original package in order to protect from light and moisture.  
Do not store above 25 °C.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

|                                                  |
|--------------------------------------------------|
| <b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b> |
|--------------------------------------------------|

For animal treatment only.

|                                                                    |
|--------------------------------------------------------------------|
| <b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b> |
|--------------------------------------------------------------------|

Keep out of the sight and reach of children.

|                                                       |
|-------------------------------------------------------|
| <b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b> |
|-------------------------------------------------------|

Chanelle Pharmaceuticals Manufacturing Limited.

|                                            |
|--------------------------------------------|
| <b>14. MARKETING AUTHORISATION NUMBERS</b> |
|--------------------------------------------|

EU/2/21/280/002 (3 pipettes)

EU/2/21/280/008 (1 pipette)

|                         |
|-------------------------|
| <b>15. BATCH NUMBER</b> |
|-------------------------|

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARDBOARD BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat 40 mg / 10 mg spot-on solution

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 0.4 ml pipette contains 40 mg imidacloprid and 10 mg moxidectin.

**3. PACKAGE SIZE**

1 pipette  
3 pipettes

**4. TARGET SPECIES**

For small dogs weighing 4 kg or less.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Spot-on use.  
For external use only.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Store in the original package in order to protect from light and moisture.  
Do not store above 25 °C.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

|                                                  |
|--------------------------------------------------|
| <b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b> |
|--------------------------------------------------|

For animal treatment only.

|                                                                    |
|--------------------------------------------------------------------|
| <b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b> |
|--------------------------------------------------------------------|

Keep out of the sight and reach of children.

|                                                       |
|-------------------------------------------------------|
| <b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b> |
|-------------------------------------------------------|

Chanelle Pharmaceuticals Manufacturing Limited.

|                                            |
|--------------------------------------------|
| <b>14. MARKETING AUTHORISATION NUMBERS</b> |
|--------------------------------------------|

EU/2/21/280/003 (3 pipettes)  
EU/2/21/280/009 (1 pipette)

|                         |
|-------------------------|
| <b>15. BATCH NUMBER</b> |
|-------------------------|

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARDBOARD BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat 100 mg / 25 mg spot-on solution

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 1 ml pipette contains 100 mg imidacloprid and 25 mg moxidectin.

**3. PACKAGE SIZE**

1 pipette  
3 pipettes

**4. TARGET SPECIES**

For medium dogs weighing >4 to 10 kg.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Spot-on use.  
For external use only.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Store in the original package in order to protect from light and moisture.  
Do not store above 25 °C.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

|                                                  |
|--------------------------------------------------|
| <b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b> |
|--------------------------------------------------|

For animal treatment only.

|                                                                    |
|--------------------------------------------------------------------|
| <b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b> |
|--------------------------------------------------------------------|

Keep out of the sight and reach of children.

|                                                       |
|-------------------------------------------------------|
| <b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b> |
|-------------------------------------------------------|

Chanelle Pharmaceuticals Manufacturing Limited.

|                                            |
|--------------------------------------------|
| <b>14. MARKETING AUTHORISATION NUMBERS</b> |
|--------------------------------------------|

EU/2/21/280/004 (3 pipettes)  
EU/2/21/280/010 (1 pipette)

|                         |
|-------------------------|
| <b>15. BATCH NUMBER</b> |
|-------------------------|

Lot {number}



**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARDBOARD BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat 250 mg / 62.5 mg spot-on solution

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 2.5 ml pipette contains 250 mg imidacloprid and 62.5 mg moxidectin.

**3. PACKAGE SIZE**

1 pipette  
3 pipettes

**4. TARGET SPECIES**

For large dogs weighing >10 to 25 kg.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Spot-on use.  
For external use only.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Store in the original package in order to protect from light and moisture.  
Do not store above 25 °C.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

|                                                  |
|--------------------------------------------------|
| <b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b> |
|--------------------------------------------------|

For animal treatment only.

|                                                                    |
|--------------------------------------------------------------------|
| <b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b> |
|--------------------------------------------------------------------|

Keep out of the sight and reach of children.

|                                                       |
|-------------------------------------------------------|
| <b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b> |
|-------------------------------------------------------|

Chanelle Pharmaceuticals Manufacturing Limited.

|                                            |
|--------------------------------------------|
| <b>14. MARKETING AUTHORISATION NUMBERS</b> |
|--------------------------------------------|

EU/2/21/280/005 (3 pipettes)  
EU/2/21/280/011 (1 pipette)

|                         |
|-------------------------|
| <b>15. BATCH NUMBER</b> |
|-------------------------|

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARDBOARD BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat 400 mg / 100 mg spot-on solution

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 4 ml pipette contains 400 mg imidacloprid and 100 mg moxidectin.

**3. PACKAGE SIZE**

1 pipette  
3 pipettes

**4. TARGET SPECIES**

For extra-large dogs weighing >25 to 40 kg.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Spot-on use.  
For external use only.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Store in the original package in order to protect from light and moisture.  
Do not store above 25 °C.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

|                                                  |
|--------------------------------------------------|
| <b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b> |
|--------------------------------------------------|

For animal treatment only.

|                                                                    |
|--------------------------------------------------------------------|
| <b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b> |
|--------------------------------------------------------------------|

Keep out of the sight and reach of children.

|                                                       |
|-------------------------------------------------------|
| <b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b> |
|-------------------------------------------------------|

Chanelle Pharmaceuticals Manufacturing Limited.

|                                            |
|--------------------------------------------|
| <b>14. MARKETING AUTHORISATION NUMBERS</b> |
|--------------------------------------------|

EU/2/21/280/006 (3 pipettes)

EU/2/21/280/012 (1 pipette)

|                         |
|-------------------------|
| <b>15. BATCH NUMBER</b> |
|-------------------------|

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****SACHET (PET/Alu/NYLON/LDPE)****Imoxat for small cats and ferrets****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat spot-on solution

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**40 mg imidacloprid and 4 mg moxidectin.  
(≤ 4 kg)**4. BATCH NUMBER**

Lot {number}

**5. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****SACHET (PET/Alu/NYLON/LDPE)****Imoxat for large cats****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat spot-on solution

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

80 mg imidacloprid and 8 mg moxidectin

(&gt; 4–8 kg)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****SACHET (PET/Alu/NYLON/LDPE)****Imoxat for small dogs****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat spot-on solution

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**40 mg imidacloprid and 10 mg moxidectin  
(≤ 4 kg)**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**SACHET (PET/Alu/NYLON/LDPE)**  
**Imoxat for medium dogs**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat spot-on solution



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

100 mg imidacloprid and 25 mg moxidectin  
(> 4–10 kg)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}



**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****SACHET (PET/Alu/NYLON/LDPE)****Imoxat for large dogs****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat spot-on solution

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**250 mg imidacloprid and 62.5 mg moxidectin  
(> 10–25 kg)**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****SACHET (PET/Alu/NYLON/LDPE)****Imoxat for extra-large dogs****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat spot-on solution

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**400 mg imidacloprid and 100 mg moxidectin  
(> 25–40 kg)**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PIPETTE (PP/COC/EVOH/PP)**

**Imoxat for small cats and ferrets**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

(≤ 4 kg)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PIPETTE (PP/COC/EVOH/PP)**

**Imoxat for large cats**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

(> 4–8 kg)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PIPETTE (PP/COC/EVOH/PP)**

**Imoxat for small dogs**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

(≤ 4 kg)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PIPETTE (PP/COC/EVOH/PP)**

**Imoxat for medium dogs**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

(> 4–10 kg)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PIPETTE (PP/COC/EVOH/PP)**

**Imoxat for large dogs**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

(> 10–25 kg)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PIPETTE (PP/COC/EVOH/PP)**

**Imoxat for extra-large dogs**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Imoxat



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

(> 25–40 kg)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}



## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Imoxat 40 mg / 4 mg spot-on solution for small cats and ferrets

Imoxat 80 mg / 8 mg spot-on solution for large cats

### 2. Composition

Each unit dose pipette contains:

|                                                  | Unit dose | Imidacloprid | Moxidectin |
|--------------------------------------------------|-----------|--------------|------------|
| Imoxat for small cats ( $\leq 4$ kg) and ferrets | 0.4 ml    | 40 mg        | 4 mg       |
| Imoxat for large cats ( $> 4-8$ kg)              | 0.8 ml    | 80 mg        | 8 mg       |

Excipients: 1 mg/ml butylhydroxytoluene (E321).

Colourless to yellow solution.

### 3. Target species



### 4. Indications for use

**For cats** suffering from, or at risk from, mixed parasitic infections. The veterinary medicinal product is only indicated when use against fleas and one or more of the other target parasites is indicated at the same time:

- the treatment and prevention of flea infestation (*Ctenocephalides felis*),
- the treatment of ear mite infestation (*Otodectes cynotis*),
- the treatment of notoedric mange (*Notoedres cati*),
- the treatment of the lungworm *Eucoleus aerophilus* (syn. *Capillaria aerophila*) (adults),
- the prevention of lungworm disease (L3/L4 larvae of *Aelurostrongylus abstrusus*),
- the treatment of the lungworm *Aelurostrongylus abstrusus* (adults),
- the treatment of the eye worm *Thelazia callipaeda* (adults),
- the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*),
- the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of *Toxocara cati* and *Ancylostoma tubaeforme*).

The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

**For ferrets** suffering from, or at risk from, mixed parasitic infections. The veterinary medicinal product is only indicated when use against fleas and the prevention of heartworm disease is indicated at the same time:

- the treatment and prevention of flea infestation (*Ctenocephalides felis*),
- the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*).

### 5. Contraindications

Do not use in kittens under 9 weeks of age.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

For ferrets: do not use Imoxat for large cats (0.8 ml) or Imoxat for dogs (any size).

Do not use in dogs. Instead, the corresponding “Imoxat for dog” product, which contains 100 mg/ml imidacloprid and 25 mg/ml moxidectin, must be used for dogs.

Do not use on canaries.

## **6. Special warnings**

The veterinary medicinal product’s efficacy has not been tested in ferrets weighing over 2 kg and therefore the duration of effect might be shorter in these animals.

Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the product.

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each individual animal.

The possibility that other animals in the same household can be a source of re-infection with fleas, mites, gastrointestinal nematodes, heartworm and/or lungworm should be considered, and these should be treated as necessary with an appropriate product.

### Special precautions for safe use in the target species:

Treatment of cats weighing less than 1 kg and ferrets weighing less than 0.8 kg should be based on a benefit-risk assessment.

There is limited experience on the use of the veterinary medicinal product in sick and debilitated animals, thus the veterinary medicinal product should only be used based on a benefit-risk assessment for these animals.

Do not apply in the mouth, in the eyes or the ears of the animal.

Care should be taken that the veterinary medicinal product is not ingested by animals and does not come into contact with the eyes or mouth of the recipient and/or other animals. Consider carefully the correct application method described in section “Advice on correct administration”, especially that the veterinary medicinal product should be applied to the site specified in order to minimise the risk for the animal to lick the veterinary medicinal product. Do not allow recently treated animals to groom each other. Do not allow treated animals to come into contact with untreated animals until the application site is dry.

In case of accidental oral uptake, symptomatic treatment should be administered. There is no known specific antidote. The use of activated charcoal may be beneficial.

It is recommended that cats and ferrets living in, or travelling to, areas endemic for heartworm are treated monthly with the veterinary medicinal product to protect them from heartworm disease.

Whilst the accuracy of diagnosis of heartworm infection is limited, it is recommended that attempts be made to check the heartworm status of any cat and ferret aged over 6 months, prior to beginning of prophylactic treatment, as use of the veterinary medicinal product on cats or ferrets which have adult

heartworm may cause serious adverse effects, including death. If adult heartworm infection is diagnosed, the infection should be treated in accordance with current scientific knowledge.

In certain individual cats *Notoedres cati* infestation may be severe. In these severe cases concomitant supportive treatment is necessary as treatment with the veterinary medicinal product alone may not be sufficient to prevent death of the animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Avoid contact with skin, eyes or mouth.

Do not eat, drink or smoke during application.

Wash hands thoroughly after use.

After application do not stroke or groom animals until the application site is dry.

In case of accidental spillage onto skin, wash off immediately with soap and water.

People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the veterinary medicinal product with caution. In very rare cases the veterinary medicinal product may cause skin sensitisation or transient skin reactions (for example numbness, irritation or burning/tingling sensation).

In very rare cases the veterinary medicinal product may cause respiratory irritation in sensitive individuals.

If the veterinary medicinal product accidentally gets into eyes, they should be thoroughly flushed with water.

If skin or eye symptoms persist, or the veterinary medicinal product is accidentally swallowed, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy, lactation and fertility:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species. Therefore, the use of the product is not recommended in animals intended for breeding or during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

During treatment with the veterinary medicinal product no other antiparasitic macrocyclic lactone should be administered.

No interactions between the veterinary medicinal product and routinely used veterinary medicinal products or medical or surgical procedures have been observed.

Overdose:

Up to 10 times the recommended dose was tolerated in cats with no evidence of adverse effects or undesirable clinical signs.

The veterinary medicinal product was administered to kittens at up to 5 times the recommended dose, every 2 weeks for 6 treatments, and there were no serious safety concerns. Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.

After accidental oral ingestion or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur in very rare cases.

The veterinary medicinal product was administered to ferrets at 5 times the recommended dose, every 2 weeks for 4, and there was no evidence of adverse effects or undesirable clinical signs.

Other precautions:

The solvent in the veterinary medicinal product may stain or damage certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

Imidacloprid is toxic for birds, especially canaries.

Special precautions for the protection of the environment:  
None.

## **7. Adverse events**

Cats and ferrets

|                                                                                |                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rare<br>(1 to 10 animals / 10 000 animals treated):                            | Application site greasy fur <sup>1</sup><br>Vomiting <sup>1</sup><br>Hypersensitivity reactions <sup>6</sup><br>Erythema (redness) <sup>1</sup>                                                              |
| Very rare<br>(<1 animal / 10 000 animals treated, including isolated reports): | Behavioural disorder (e.g. agitation) <sup>2</sup><br>Hypersalivation <sup>4</sup><br>Neurological signs <sup>3</sup><br>Pruritus (itching) <sup>5</sup><br>Lethargy <sup>2</sup> , Inappetence <sup>2</sup> |

<sup>1</sup>These signs disappear without further treatment.

<sup>2</sup>Transiently noted and related to sensation at application site.

<sup>3</sup>If the animal licks the application site after treatment, (most of which are transient).

<sup>4</sup>The veterinary medicinal product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application site.

<sup>5</sup>Transient in cats.

<sup>6</sup>Local.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## **8. Dosage for each species, routes and method of administration**

To ensure a correct dosage, body weight should be determined as accurately as possible.

### Method of administration

Spot-on use.

For external use only.

To prevent licking, apply topically to the skin restricting the area of application to the animal's neck at the base of the skull.

### Dosage schedule for cats:

The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 1 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight of the veterinary medicinal product.

For treatment or prevention of infestations with the parasites indicated for use of this veterinary medicinal product, the need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal's lifestyle.

| Weight of cat [kg] | Pipette size to be used                 | Volume [ml] | Imidacloprid [mg/kg bw] | Moxidectin [mg/kg bw] |
|--------------------|-----------------------------------------|-------------|-------------------------|-----------------------|
| ≤ 4 kg             | Imoxat for small cats and ferrets       | 0.4         | minimum of 10           | minimum of 1          |
| > 4–8 kg           | Imoxat for large cats                   | 0.8         | 10–20                   | 1–2                   |
| > 8 kg             | the appropriate combination of pipettes |             |                         |                       |

#### Flea treatment and prevention (*Ctenocephalides felis*)

One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine animal treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The veterinary medicinal product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

#### Treatment of ear mite infestation (*Otodectes cynotis*)

A single dose of the veterinary medicinal product should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

#### Treatment of notoedric mange (*Notoedres cati*)

A single dose of the veterinary medicinal product should be administered.

#### Treatment of the lungworm *Eucoleus aerophilus* (syn. *Capillaria aerophila*) (adults)

A single dose of the veterinary medicinal product should be administered.

#### Prevention of *Aelurostrongylus abstrusus*

The veterinary medicinal product should be administered monthly.

#### Treatment of *Aelurostrongylus abstrusus*

The veterinary medicinal product should be administered monthly for three consecutive months.

#### Treatment of the eye worm *Thelazia callipaeda* (adults)

A single dose of the veterinary medicinal product should be administered.

#### Heartworm prevention (*Dirofilaria immitis*)

Cats in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with the veterinary medicinal product, the advice provided in section "Special warnings" should be considered.

For prevention of heartworm disease, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The veterinary medicinal product may be administered throughout the year. The first dose may be given after first possible exposure to mosquitoes, but not more than one month after this exposure. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with the veterinary medicinal product must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of cats having heartworm. Therefore, they can be treated without special precautions.

#### Roundworm and hookworm treatment (*Toxocara cati* and *Ancylostoma tubaeforme*)

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas non-endemic for heartworm, the veterinary medicinal product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

#### Dosage schedule for ferrets:

One pipette of Imoxat spot-on solution for small cats (0.4 ml) should be administered per animal. Do not exceed the recommended dose.

For treatment or prevention of infestations with the parasites indicated for use of this veterinary medicinal product, the need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal's lifestyle.

#### Flea treatment and prevention (*Ctenocephalides felis*)

One treatment prevents future flea infestation for 3 weeks. Under heavy flea pressure it may be necessary to repeat administration after 2 weeks.

#### Heartworm prevention (*Dirofilaria immitis*)

Ferrets in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with the veterinary medicinal product, the advice provided in section "Special warnings" should be considered.


For prevention of heartworm disease, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The veterinary medicinal product may be administered throughout the year. The first dose may be given after first possible exposure to mosquitoes, but not more than one month after this exposure. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.


In non-endemic areas there should be no risk of ferrets having heartworm. Therefore they can be treated without special precautions.

### **9. Advice on correct administration**

Remove one pipette from the package. Tap the narrow part of the tube to ensure the contents are within the main body of the tube. Snap back the tip of the pipette to enable the contents to be expelled.

Part the fur on the animal's neck at the base of the skull until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin. Application at the base of the skull will minimise the opportunity for the animal to lick the veterinary medicinal product. Apply only to undamaged skin.





#### **10. Withdrawal periods**

Not applicable.

#### **11. Special storage precautions**

Keep out of the sight and reach of children.

Store in the original package in order to protect from light and moisture.

Do not store above 25 °C.

Do not use this veterinary medicinal product after the expiry date stated on the label and carton. The expiry date refers to the last day of that month.

#### **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

This veterinary medicinal product should not enter water courses as this may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

#### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

#### **14. Marketing authorisation numbers and pack sizes**

EU/2/21/280/001

EU/2/21/280/007

EU/2/21/280/002

EU/2/21/280/008

Pack sizes: 0.4 ml and 0.8 ml per pipette.

Each cardboard box contains 1 or 3 pipettes in individual foil sachets



Not all pack sizes may be marketed.

**15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

**16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
IE - Ireland

Local representatives and contact details to report suspected adverse events:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irelande  
Tel: + 353 91 841788

**Lietuva**

Dimedium Lietuva UAB  
Islandijos pl. 217-13, LT-49165  
Kaunas, Lithuania  
Tel: +370 615 64241

**Република България**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ирландия  
Tel: + 353 91 841788

**Luxembourg/Luxemburg**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irelande  
Tel: + 353 91 841788

**Česká republika**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irsko  
Tel: + 353 91 841788

**Magyarország**

Alpha-Vet  
Hofherr Albert út 42.  
1194 Budapest,  
Magyarországand  
Tel: +36 22 516 402

**Danmark**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irland  
Tel: + 353 91 841788

**Deutschland**

aniMedica GmbH  
a LIVISTO company  
Im Südfeld 9  
D-48308 Senden-Bösensell  
Tel.: +49 2536 3302-0

**Eesti**

AS Dimedium  
Roheline 9, Tahtvere,  
61410 Tartu, Estonia  
Tel: +372 739 0660

**Ελλάδα**

PROVET S.A.  
TK 19300 Ασπρόπυργος, Αττική  
Ελλάδα  
Τηλ: +30 2105508777  
e-mail: pv@provet.gr

**España**

Industrial Veterinaria, S.A.  
a LIVISTO company  
Esmeralda, 19  
08950 Esplugues de Llobregat  
(Barcelona) España  
Tel.: +34 934 706 270

**France**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irlande  
Tel: + 353 91 841788

**Hrvatska**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irska  
Tel: + 353 91 841788

**Malta**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
L-irlanda  
Tel: + 353 91 841788

**Nederland**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ierland  
Tel: + 353 91 841788

**Norge**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irland  
Tel: + 353 91 841788

**Österreich**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irland  
Tel: + 353 91 841788

**Polska**

LIVISTO Sp. z o.o.  
ul. Chwaszczyńska 198 a  
81-571 Gdynia  
Polska  
Tel.: +48 58 572 24 38

**Portugal**

VETLIMA, S.A.  
Centro Empresarial da Rainha, Lote 27  
2050-501 Vila Nova da Rainha  
Portugal  
Tel +351 964404163  
Email: farmacovigilancia@vetlima.com

**România**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irlanda  
Tel: + 353 91 841788

**Ireland**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ireland  
Tel: + 353 91 841788

**Slovenija**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irska  
Tel: + 353 91 841788

**Ísland**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Írland  
Tel: + 353 91 841788

**Slovenská republika**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Írsko  
Tel: + 353 91 841788

**Italia**

Industria Italiana Integratori TREI S.p.A.  
a LIVISTO company  
Via Affarosa 4  
42010 Rio Saliceto (RE)  
Italia  
Tel.: +39 0522640711

**Suomi/Finland**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irlanti  
Tel: + 353 91 841788

**Κύπρος**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ιρλανδία  
Tel: + 353 91 841788

**Sverige**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ireland  
Tel: + 353 91 841788

**Latvija**

AS Dimedijum Latvija  
Ozolu iela 28, Jaunmarupe,  
Marupes novads, LV-2166, Latvia  
Tel: +371 67610001

**United Kingdom (Northern Ireland)**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ireland  
Tel: + 353 91 841788

**17. Other information**

Imidacloprid is effective against larval flea stages and adult fleas. Flea larvae in the pet's surroundings are killed after contact with a pet treated with the product.

The veterinary medicinal product has a persistent action and protects cats for 4 weeks after a single application against reinfection with *Dirofilaria immitis*.

Studies evaluating the pharmacokinetic behaviour of moxidectin after multiple applications have indicated that steady state serum levels are achieved following approximately 4 consecutive monthly treatments in cats.

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Imoxat 40 mg / 10 mg spot-on solution for small dogs  
Imoxat 100 mg / 25 mg spot-on solution for medium dogs  
Imoxat 250 mg / 62.5 mg spot-on solution for large dogs  
Imoxat 400 mg / 100 mg spot-on solution for extra-large dogs

### 2. Composition

Each unit dose pipette contains:

|                                              | Unit dose | Imidacloprid | Moxidectin |
|----------------------------------------------|-----------|--------------|------------|
| Imoxat for small dogs ( $\leq 4$ kg)         | 0.4 ml    | 40 mg        | 10 mg      |
| Imoxat for medium dogs ( $> 4$ –10 kg)       | 1.0 ml    | 100 mg       | 25 mg      |
| Imoxat for large dogs ( $> 10$ –25 kg)       | 2.5 ml    | 250 mg       | 62.5 mg    |
| Imoxat for extra-large dogs ( $> 25$ –40 kg) | 4.0 ml    | 400 mg       | 100 mg     |

Excipients: 1 mg/ml butylhydroxytoluene (E321).  
Colourless to yellow solution.

### 3. Target species

Dogs.



### 4. Indications for use

**For dogs** suffering from, or at risk from, mixed parasitic infections. The veterinary medicinal product is only indicated when use against fleas and one or more of the other target parasites is indicated at the same time:

- the treatment and prevention of flea infestation (*Ctenocephalides felis*),
- the treatment of biting lice (*Trichodectes canis*),
- the treatment of ear mite infestation (*Otodectes cynotis*), sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*), demodicosis (caused by *Demodex canis*),
- the prevention of heartworm disease (L3 and L4 larvae of *Dirofilaria immitis*),
- the treatment of circulating microfilariae (*Dirofilaria immitis*),
- the treatment of cutaneous dirofilariosis (adult stages of *Dirofilaria repens*)
- the prevention of cutaneous dirofilariosis (L3 larvae of *Dirofilaria repens*),
- the reduction of circulating microfilariae (*Dirofilaria repens*),
- the prevention of angiostrongylosis (L4 larvae and immature adults of *Angiostrongylus vasorum*),
- the treatment of *Angiostrongylus vasorum* and *Crenosoma vulpis*,
- the prevention of spirocercosis (*Spirocerca lupi*),
- the treatment of *Eucoleus* (syn. *Capillaria*) *boehmi* (adults),
- the treatment of the eye worm *Thelazia callipaeda* (adults),
- the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and

adults of *Toxocara canis*, *Ancylostoma caninum* and *Uncinaria stenocephala*, adults of *Toxascaris leonina* and *Trichuris vulpis*).

The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

## **5. Contraindications**

Do not use in puppies under 7 weeks of age.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

Do not use in dogs classified as Class 4 for heartworm disease as the safety of the product has not been evaluated in this animal group.

Do not use in cats. Instead, the corresponding “Imoxat for cats” product (0.4 or 0.8 ml), which contains 100 mg/ml imidacloprid and 10 mg/ml moxidectin, must be used for cats.

Do not use in ferrets. Only “Imoxat for small cats and ferrets” (0.4 ml) must be used for ferrets.

Do not use on canaries.

## **6. Special warnings**

### Special warnings:

Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the veterinary medicinal product.

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each individual animal.

The possibility that other animals in the same household can be a source of re-infection with fleas, mites, gastrointestinal nematodes, heartworm and/or lungworm should be considered, and these should be treated as necessary with an appropriate product.

Efficacy against adult *Dirofilaria repens* has not been tested under field conditions.

### Special precautions for safe use in the target species:

Treatment of animals weighing less than 1 kg should be based on a benefit-risk assessment.

There is limited experience on the use of the veterinary medicinal product in sick and debilitated animals, thus the veterinary medicinal product should only be used based on a benefit-risk assessment for these animals.

Do not apply in the mouth, in the eyes or the ears of the animal.

Care should be taken that the veterinary medicinal product is not ingested by animals and does not come into contact with the eyes or mouth of the recipient and/or other animals. Consider carefully the correct application method described in section “Advice on correct administration”, especially that the veterinary medicinal product should be applied to the site specified in order to minimise the risk for the animal to lick the veterinary medicinal product. Do not allow recently treated animals to groom each other. Do not allow treated animals to come into contact with untreated animals until the application site is dry.

In case of accidental oral uptake, symptomatic treatment should be administered. There is no known specific antidote. The use of activated charcoal may be beneficial.

When the veterinary medicinal product is applied in 3 to 4 separate spots, specific care should be taken to prevent the animal licking the application sites.

This veterinary medicinal product contains moxidectin (a macrocyclic lactone), therefore special care should be taken with Collie or Old English Sheep dogs and related breeds or crossbreeds, to correctly administer the veterinary medicinal product as described under the section “Advice on correct administration”; in particular, oral uptake by Collie or Old English Sheep dogs and related breeds or crossbreeds should be prevented.

The safety of the veterinary medicinal product has only been evaluated in dogs classified as either Class 1 or 2 for heartworm disease in laboratory studies and in a few Class 3 dogs in a field study. Therefore the use in dogs with obvious or severe symptoms of the disease should be based on a careful benefit-risk assessment by the treating veterinarian.

Although experimental overdosage studies have shown that the veterinary medicinal product may be safely administered to dogs infected with adult heartworms, it has no therapeutic efficacy against adult *Dirofilaria immitis*. It is therefore recommended that all dogs 6 months of age or more, living in areas endemic for heartworm, should be tested for existing adult heartworm infection before being treated with the veterinary medicinal product. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of the veterinary medicinal product has not been evaluated when administered on the same day as an adulticide.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Avoid contact with skin, eyes or mouth.

Do not eat, drink or smoke during application.

Wash hands thoroughly after use.

After application do not stroke or groom animals until the application site is dry.

In case of accidental spillage onto skin, wash off immediately with soap and water.

People with known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the veterinary medicinal product with caution. In very rare cases the veterinary medicinal product may cause skin sensitisation or transient skin reactions (for example numbness, irritation or burning/tingling sensation).

In very rare cases the veterinary medicinal product may cause respiratory irritation in sensitive individuals.

If the veterinary medicinal product accidentally gets into eyes, they should be thoroughly flushed with water.

If skin or eye symptoms persist, or the veterinary medicinal product is accidentally swallowed, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy, lactation and fertility:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species. Therefore, the use of the product is not recommended in animals intended for breeding or during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

During treatment with the veterinary medicinal product no other antiparasitic macrocyclic lactone should be administered.

No interactions between the veterinary medicinal product and routinely used veterinary medicinal products or medical or surgical procedures have been observed.

Safety of the veterinary medicinal product when administered on the same day as an adulticide to remove adult heartworms has not been evaluated.

#### Overdose:

Up to 10 times the recommended dose was tolerated in adult dogs with no evidence of adverse effects or undesirable clinical signs. Five times the recommended minimum dose applied at weekly intervals for 17 weeks was investigated in dogs aged over 6 months and tolerated with no evidence of adverse effects or undesirable clinical signs.

The veterinary medicinal product was administered to puppies at up to 5 times the recommended dose, every 2 weeks for 6 treatments, and there were no serious safety concerns. Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.

After accidental oral ingestion or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur in very rare cases.

Ivermectin-sensitive Collie dogs tolerated up to 5 times the recommended dose repeated at monthly intervals without any adverse effects, but the safety of application at weekly intervals has not been investigated in ivermectin-sensitive Collie dogs. When 40 % of the unit dose was given orally, severe neurological signs were observed. Oral administration of 10 % of the recommended dose produced no adverse effects.

Dogs infected with adult heartworms tolerated up to 5 times the recommended dose, every 2 weeks for 3 treatments, without any adverse effects.

#### Other precautions:

The solvent in the veterinary medicinal product may stain or damage certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

Imidacloprid is toxic for birds, especially canaries.

#### Special precautions for the protection of the environment:

The veterinary medicinal product should not enter water courses as this may be dangerous for fish and other aquatic organism: moxidectin is highly toxic to aquatic organisms. Dogs should not be allowed to swim in surface waters for 4 days after treatment.

## **7. Adverse events**

Dogs

|                                                                                |                                                                                                                                                                                                                                                                                                                                            |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Common<br>(1 to 10 animals / 100 animals treated):                             | Cough <sup>1</sup> , Dyspnoea (difficulty breathing) <sup>1</sup> , Tachypnoea (rapid breathing) <sup>1</sup><br>Diarrhoea <sup>1</sup> , Vomiting <sup>1</sup><br>Inappetence <sup>1</sup> , Lethargy <sup>1</sup>                                                                                                                        |
| Rare<br>(1 to 10 animals / 10 000 animals treated):                            | Vomiting                                                                                                                                                                                                                                                                                                                                   |
| Very rare<br>(<1 animal / 10 000 animals treated, including isolated reports): | Application site greasy fur <sup>2</sup> , Application site hair loss <sup>2</sup> , Application site itching <sup>2</sup> , Application site reddening. <sup>2</sup><br>Behavioural changes (eg. agitation) <sup>3</sup><br>Hypersalivation <sup>4</sup><br>Neurological signs (e.g. ataxia (incoordination), muscle tremor) <sup>5</sup> |

|  |                                                                                     |
|--|-------------------------------------------------------------------------------------|
|  | Pruritus (itching) <sup>6</sup><br>Inappetence <sup>3</sup> , Lethargy <sup>3</sup> |
|--|-------------------------------------------------------------------------------------|

<sup>1</sup>In heartworm positive dogs with microfilaraemia there is a risk of gastrointestinal and severe respiratory signs that may require prompt veterinary treatment.

<sup>2</sup>Transient local skin sensitivity reactions, These signs disappear without further treatment.

<sup>3</sup>Transiently noted and related to sensation at application site.

<sup>4</sup>May occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application sites.

<sup>5</sup>Most neurological signs occur transiently.

<sup>6</sup>In dogs, transient.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

## 8. Dosage for each species, routes and method of administration

To ensure a correct dosage, body weight should be determined as accurately as possible.

### Method of administration

Spot-on use.

For external use only.

Apply topically to the skin between the shoulder blades.

### Dosage schedule

The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight of the veterinary medicinal product.

For treatment or prevention of infestations with the parasites indicated for use of this veterinary medicinal product, the need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal's lifestyle.

| Weight of dog [kg] | Pipette size to be used                 | Volume [ml] | Imidacloprid [mg/kg bw] | Moxidectin [mg/kg bw] |
|--------------------|-----------------------------------------|-------------|-------------------------|-----------------------|
| ≤ 4 kg             | Imoxat for small dogs                   | 0.4         | minimum of 10           | minimum of 2.5        |
| > 4–10 kg          | Imoxat for medium dogs                  | 1.0         | 10–25                   | 2.5–6.25              |
| > 10–25 kg         | Imoxat for large dogs                   | 2.5         | 10–25                   | 2.5–6.25              |
| > 25–40 kg         | Imoxat for extra-large dogs             | 4.0         | 10–16                   | 2.5–4                 |
| > 40 kg            | the appropriate combination of pipettes |             |                         |                       |

### Flea treatment and prevention (*Ctenocephalides felis*)

One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine animal treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the



household flea population. The veterinary medicinal product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

Treatment of biting lice (*Trichodectes canis*)

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

Treatment of ear mite infestation (*Otodectes cynotis*)

A single dose of the veterinary medicinal product should be administered. Loose debris should be gently removed from the external ear canal at each treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

Treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*)

A single dose should be administered twice 4 weeks apart.

Treatment of demodicosis (caused by *Demodex canis*)

The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against *Demodex canis* and leads to a marked improvement of clinical signs particularly in mild to moderate cases. Especially severe cases may require more prolonged and more frequent treatment. To achieve the best possible response in these severe cases, at the discretion of the veterinarian, the veterinary medicinal product can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian.

As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

Prevention of heartworm disease (*D. immitis*)

Dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with the veterinary medicinal product, the advice provided in section "Special warnings" should be considered.

For prevention of heartworm disease, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit *D. immitis*) are present. The veterinary medicinal product may be administered throughout the year. The first dose may be given after first possible exposure to mosquitoes, but not more than one month after this exposure. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with the veterinary medicinal product must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of dogs having heartworm. Therefore they can be treated without special precautions.

Prevention of cutaneous dirofilariosis (skinworm) (*D. repens*)

For prevention of cutaneous dirofilariosis, the veterinary medicinal product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit *D. repens* larvae) are present. The veterinary medicinal product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month.

Treatment of microfilariae (*D. immitis*)

The veterinary medicinal product should be administered monthly for two consecutive months.

Treatment of cutaneous dirofilariosis (skin worm) (adult stages of *Dirofilaria repens*)

The veterinary medicinal product should be administered monthly for six consecutive months.

Reduction of microfilariae (skin worm) (*D. repens*)

The veterinary medicinal product should be administered monthly for four consecutive months.

Treatment and prevention of *Angiostrongylus vasorum*

A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

In endemic areas regular monthly application will prevent angiostrongylosis and patent infection with *Angiostrongylus vasorum*.

Treatment of *Crenosoma vulpis*

A single dose should be administered.

Prevention of spirocercosis (*Spirocerca lupi*):

The veterinary medicinal product should be administered monthly.

Treatment of *Eucoleus* (syn. *Capillaria*) *boehmi* (adults)

The veterinary medicinal product should be administered monthly for two consecutive months. It is advisable to prevent auto-coprophagia between the two treatments in order to prevent possible reinfection.

Treatment of the eye worm *Thelazia callipaeda* (adults)

A single dose of the veterinary medicinal product should be administered.

Roundworm, hookworm and whipworm treatment (*Toxocara canis*, *Ancylostoma caninum*, *Uncinaria stenocephala*, *Toxascaris leonina* and *Trichuris vulpis*).

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas non-endemic for heartworm, the veterinary medicinal product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Studies have shown that monthly treatment of dogs will prevent infections caused by *Uncinaria stenocephala*.

## **9. Advice on correct administration**

Remove one pipette from the package. Tap the narrow part of the tube to ensure the contents are within the main body of the tube. Snap back the tip of the pipette to enable the contents to be expelled.


For dogs up to 25 kg:

With the dog in a standing position, part the coat between the shoulder blades until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin.

For dogs of more than 25 kg:

For easy application the dog should be standing. The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail. At each spot, part the coat until the skin is visible. Wherever possible apply to undamaged skin. Place the

tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin. Do not apply an excessive amount of solution at any one spot, as that could cause some of the product to run down the animal's side.



#### **10. Withdrawal periods**

Not applicable.

#### **11. Special storage precautions**

Keep out of the sight and reach of children.

Store in the original package in order to protect from light and moisture.

Do not store above 25 °C.

Do not use this veterinary medicinal product after the expiry date stated on the label and carton. The expiry date refers to the last day of that month.

#### **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

This veterinary medicinal product should not enter water courses as this may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. Marketing authorisation numbers and pack sizes**

EU/2/21/280/003

EU/2/21/280/009

EU/2/21/280/004

EU/2/21/280/010

EU/2/21/280/005

EU/2/21/280/011

EU/2/21/280/006

EU/2/21/280/012

Pack sizes: 0.4 ml 1.0 ml, 2.5 ml and 4.0 ml per pipette.

Each cardboard box contains 1 or 3 pipettes in individual foil sachets

Not all pack sizes may be marketed.

### **15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

### **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Limited.

Loughrea

Co. Galway

IE – Ireland

Local representatives and contact details to report suspected adverse events:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

#### **België/Belgique/Belgien**

Chanelle Pharmaceuticals Manufacturing Limited.

Loughrea

Co. Galway

Irlande

Tel: + 353 91 841788

#### **Lietuva**

Dimedium Lietuva UAB

Islandijos pl. 217-13, LT-49165

Kaunas, Lithuania

Tel: +370 615 64241

**Република България**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ирландия  
Tel: + 353 91 841788

**Česká republika**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ирландия  
Tel: + 353 91 841788

**Danmark**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ирландия  
Tel: + 353 91 841788

**Deutschland**

aniMedica GmbH  
a LIVISTO company  
Im Südfeld 9  
D-48308 Senden-Bösensell  
Tel.: +49 2536 3302-0

**Eesti**

AS Dimedium  
Roheline 9, Tahtvere,  
61410 Tartu, Estonia  
Tel: +372 739 0660

**Ελλάδα**

PROVET S.A.  
TK 19300 Ασπρόπυργος, Αττική  
Ελλάδα  
Τηλ: +30 2105508777  
e-mail: pv@provet.gr

**España**

Industrial Veterinaria, S.A.  
a LIVISTO company  
Esmeralda, 19  
08950 Esplugues de Llobregat  
(Barcelona) España  
Tel.: +34 934 706 270

**Luxembourg/Luxemburg**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ирландия  
Tel: + 353 91 841788

**Magyarország**

Alpha-Vet  
Hofherr Albert út 42.  
1194 Budapest,  
Magyarország  
Tel: +36 22 516 402

**Malta**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ирландия  
Tel: + 353 91 841788

**Nederland**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ирландия  
Tel: + 353 91 841788

**Norge**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ирландия  
Tel: + 353 91 841788

**Österreich**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ирландия  
Tel: + 353 91 841788

**Polska**

LIVISTO Sp. z o.o.  
ul. Chwaszczyńska 198 a  
81-571 Gdynia  
Polska  
Tel.: +48 58 572 24 38

**France**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irlante  
Tel: + 353 91 841788

**Hrvatska**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irska  
Tel: + 353 91 841788

**Ireland**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ireland  
Tel: + 353 91 841788

**Ísland**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Írland  
Tel: + 353 91 841788

**Italia**

Industria Italiana Integratori TREI S.p.A.  
a LIVISTO company  
Via Affarosa 4  
42010 Rio Saliceto (RE)  
Italia  
Tel.: +39 0522640711

**Κύπρος**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ιρλανδία  
Tel: + 353 91 841788

**Latvija**

AS Dimedium Latvija  
Ozolu iela 28, Jaunmarupe,  
Marupes novads, LV-2166, Latvia  
Tel: +371 67610001

**Portugal**

VETLIMA, S.A.  
Centro Empresarial da Rainha, Lote 27  
2050-501 Vila Nova da Rainha  
Portugal  
Tel +351 964404163  
Email: farmacovigilancia@vetlima.com

**România**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irlanda  
Tel: + 353 91 841788

**Slovenija**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irska  
Tel: + 353 91 841788

**Slovenská republika**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Írsko  
Tel: + 353 91 841788

**Suomi/Finland**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irlanti  
Tel: + 353 91 841788

**Sverige**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Irland  
Tel: + 353 91 841788

**United Kingdom (Northern Ireland)**

Chanelle Pharmaceuticals Manufacturing Limited.  
Loughrea  
Co. Galway  
Ireland  
Tel: + 353 91 841788

## **17. Other Informations**

Imidacloprid is effective against larval flea stages and adult fleas. Flea larvae in the pet's surroundings are killed after contact with a pet treated with the product.

The veterinary medicinal product has a persistent action and protects dogs for 4 weeks after a single application against re-infection with the following parasites: *Dirofilaria immitis*, *Dirofilaria repens*, *Angiostrongylus vasorum*.

Studies evaluating the pharmacokinetic behaviour of moxidectin after multiple applications have indicated that steady state serum levels are achieved following approximately 4 consecutive monthly treatments in dogs.